<DOC>
	<DOCNO>NCT00996138</DOCNO>
	<brief_summary>This study identify preferred vaccine dosage ( antigen adjuvant ) schedule ( one two administration ) cell-derived H1N1sw monovalent vaccine healthy adult base EMEA/CHMP criterion , safety &amp; tolerability .</brief_summary>
	<brief_title>Single-blind , Dose-ranging Study Novel Swine Influenza Virus Vaccine Japanese Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Japanese adult age 20 60 year History anaphylaxis , serious vaccine reaction , hypersensitivity vaccine viral proteins excipients Administration adjuvanted influenza vaccine suspect influenza disease within 3 month prior study start Administration vaccine within 4 week prior enrollment expect seasonal influenza vaccine within 1 week History progressive severe neurological disorder</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>H1N1 subtype</keyword>
	<keyword>Adult</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Swine-Origin Influenza A H1N1 Virus</keyword>
</DOC>